USPSTF
Exact Sciences Stock Falls on Publication of New CRC Screening Cost-Effectiveness Study
The study said that Cologuard was an "inefficient screening option" for colorectal cancer given its cost as compared to other CRC screening methods.
USPSTF Formalizes Slightly Expanded BRCA Screening Recommendations
After reviewing more than 100 studies, the panel issued recommendations focused on women with a personal or family history of BRCA1/2-related cancers or high-risk ancestry.
By focusing too heavily on family history, the Preventive Services Task Force is missing many opportunities for prevention, patient advocates, industry players, and researchers say.
Epigenomics Pushes New Promotion Efforts for ProColon Test as Other Assays in Pipeline Advance
Premium
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.
USPSTF Cervical Cancer Screening Recommendations Strike Compromise on Cotesting
In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.